--- title: vVARDIS Targets $214 Million IPO With a Pitch to Change Cavity Treatment description: Rapid growth and improving margins make the dental company worth watching. Its valuation puts pressure on execution. image: https://blog.ipoprophet.com/hubfs/Vardis%20Thumbnail%20Founders.jpg --- [Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment#main-content) [![IPO\_PROPHET\_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com) - [Login](https://app.ipoprophet.com/login) Open main navigation Close main navigation - [Login](https://app.ipoprophet.com/login) [Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4) [Go Back to Home](http://www.ipoprophet.com/) [Go Back to Blog](http://www.ipoprophet.com/blog) Nov 9, 2026, 4:36:52 PM # vVARDIS Targets $214 Million IPO With a Pitch to Change Cavity Treatment ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment) ![Vardis logo](https://blog.ipoprophet.com/hs-fs/hubfs/Vardis%20logo.jpg?width=326&height=99&name=Vardis%20logo.jpg) Swiss dental company **vVARDIS Holding AG (NYSE: VVVV)** plans to offer **9.52 million shares at $21–$24**, raising approximately **$214.3 million at the $22.50 midpoint**, with an estimated economic equity valuation of **$1.29 billion**, including midpoint anti-dilution shares. Goldman Sachs and J.P. Morgan lead the offering, joined by William Blair, UBS and Deutsche Bank. ### The Business: Earlier Intervention vVARDIS markets Curodont, a peptide-based treatment designed to repair early-stage tooth decay. Its application is limited to early lesions; advanced cavities can still require conventional restoration. The investment question is whether dentists can make earlier intervention a routine part of patient care. A product that patients accept, practices repeatedly purchase and clinicians incorporate into their workflow could build a durable business. Initial adoption matters, but repeat usage will be the stronger test. The first-half comparison shows operating leverage: revenue more than tripled while operating losses narrowed. However, investors should distinguish attractive product economics from company profitability. Sales, education and infrastructure spending still absorb more than the gross profit generated. ### Preliminary Update Nine-month 2026 estimates include **$47.7–$49.2 million revenue**, approximately **86% gross margin**, **$39.7–$41.3 million net losses**, and **$9.2–$9.4 million adjusted EBITDA losses**. These figures are preliminary. Subtracting reported first-half results implies approximately **$19.1–$20.6 million in third-quarter revenue** and **positive third-quarter adjusted EBITDA of roughly $1.2–$1.4 million**. Those are IPO Prophet calculations from management’s estimates, rather than separately reported quarterly results. That potential crossover deserves attention. Investors should watch whether subsequent quarters confirm that growth can fund the commercial organization. ![Vardis financial placard](https://blog.ipoprophet.com/hs-fs/hubfs/Vardis%20financial%20placard.jpg?width=821&height=547&name=Vardis%20financial%20placard.jpg) ### Valuation and Risks Our midpoint calculation implies approximately **26 times trailing revenue through June 2026**. That leaves limited room for slower adoption or disappointing profitability. Henry Schein represented **72% of 2025 sales**. The founders retain approximately **87% voting control**. The U.S. product follows an OTC monograph pathway without product-specific FDA approval under an NDA or ANDA. Distribution concentration makes it especially important to distinguish distributor orders from sustained practice consumption. Concentrated voting control also means public investors will have limited influence over corporate decisions. *Valuation methodology: Class B shares are converted into Class A economic equivalents at 10:1; the calculation includes approximately 4.50 million midpoint anti-dilution shares.* ### IPO Prophet Perspective The appeal is straightforward: earlier treatment, expanding revenue and evidence of improving operating economics. The harder question is how much future success investors are paying for upfront. At the proposed valuation, our focus would be on repeat purchasing, sustained gross margins and confirmation of positive adjusted EBITDA. A compelling treatment story can attract attention at the IPO. Consistent execution will determine whether the stock can support its premium. [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [vVardis](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/vvardis) ## Related posts [![](https://blog.ipoprophet.com/hs-fs/hubfs/Cerebras%20Thumbnail.png?height=200&name=Cerebras%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/cerebras-targets-blockbuster-ipo-as-wafer-scale-ai-architecture-challenges-gpu-dominance) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Cerebras Systems](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/cerebras-systems) ## [Cerebras Targets Blockbuster IPO as Wafer-Scale AI Architecture Challenges GPU Dominance](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/cerebras-targets-blockbuster-ipo-as-wafer-scale-ai-architecture-challenges-gpu-dominance) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) May 6, 2026, 2:34:27 PM Cerebras Systems Inc. has filed for an initial public offering on the Nasdaq under the ticker... [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/cerebras-targets-blockbuster-ipo-as-wafer-scale-ai-architecture-challenges-gpu-dominance) [![](https://blog.ipoprophet.com/hs-fs/hubfs/EagleRock%20Land%20Thumbnail.png?height=200&name=EagleRock%20Land%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/eaglerock-land-targets-320m-ipo-as-permian-surface-and-water-infrastructure-platform-seeks-to-capitalize-on-long-t-1778518328536) [NYSE](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nyse), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [EagleRock Land](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/eaglerock-land) ## [EagleRock Land Targets $320M IPO as Permian Surface and Water Infrastructure Platform Seeks to Capitalize on Long-Term Energy Development](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/eaglerock-land-targets-320m-ipo-as-permian-surface-and-water-infrastructure-platform-seeks-to-capitalize-on-long-t-1778518328536) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) May 11, 2026, 12:53:12 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/eaglerock-land-targets-320m-ipo-as-permian-surface-and-water-infrastructure-platform-seeks-to-capitalize-on-long-t-1778518328536) [![](https://blog.ipoprophet.com/hs-fs/hubfs/City%20Therapeutics%20thumbnail.jpg?height=200&name=City%20Therapeutics%20thumbnail.jpg)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/city-therapeutics-cty-eyes-175-million-ipo-to-advance-next-generation-rnai-medicines) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Biotherapeutics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/biotherapeutics), [City Therapeutics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/city-therapeutics) ## [City Therapeutics (CTY) Eyes $175 Million IPO to Advance Next-Generation RNAi Medicines](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/city-therapeutics-cty-eyes-175-million-ipo-to-advance-next-generation-rnai-medicines) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Oct 12, 2026, 12:26:05 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/city-therapeutics-cty-eyes-175-million-ipo-to-advance-next-generation-rnai-medicines) [linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet) --- [![IPO\_PROPHET\_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com) NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE. Copyright © 2025 ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Eric Friedman", "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman" }, "dateModified" : "2026-11-09T21:36:52.580Z", "datePublished" : "2026-11-09T21:36:52.000Z", "headline" : "vVARDIS Targets $214 Million IPO With a Pitch to Change Cavity Treatment", "image" : [ "https://blog.ipoprophet.com/hubfs/Vardis%20Thumbnail%20Founders.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/vvardis-targets-214-million-ipo-with-a-pitch-to-change-cavity-treatment", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png" }, "name" : "ipoprophet.com" } } ```